Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder-Reference-Cited by-同舟云学术

Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder

Published:2017-06-22 Issue:8 Volume:20 Page:893-901
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Carter John A.¹^ORCID,Dammerman Ryan²,Frost Michael³

Affiliation:

1. EPI-Q Inc., Oak Brook, IL, USA;

2. Formerly of Braeburn Pharmaceuticals, Princeton, NJ, USA;

3. Eagleville Hospital, Eagleville, PA, USA

Funder

Braeburn Pharmaceuticals

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1341416

Reference56 articles.

1. Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51); 2016. https://www.samhsa.gov/data/. Accessed November, 15 2016

2. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States

3. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use

4. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015

5. Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making;Quality of Life Research;2024-08-08

2. Assessing the Cost-Effectiveness of Removing Supervision Requirements for Nurse Practitioners Prescribing Buprenorphine for Opioid Use Disorder;Journal of Nursing Regulation;2023-10

3. The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews;Frontiers in Psychiatry;2023-08-31

4. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model;BMC Health Services Research;2022-11-08

5. The cost-effectiveness of collegiate recovery programs;Journal of American College Health;2022-01-26